Single- and multiple-dose pharmacokinetics of ethambutol and rifampicin in a tuberculosis patient with acute respiratory distress syndrome undergoing extended daily dialysis and ECMO treatment
详细信息 查看全文
- 作者：Ann-Kathrin Strunka ; ann-kathrin.strunk@gmx.net" class="auth_mail" title="E-mail the corresponding author ; Sandra Ciesekb ; Julius J. Schmidta ; Christian Kü ; hnc ; Marius M. Hoeperd ; Tobias Welted ; Jan T. Kielsteina
- 关键词：Active tuberculosis ; Ethambutol ; Rifampicin ; Renal replacement therapy
- 刊名：International Journal of Infectious Diseases
- 出版年：2016
- 出版时间：January 2016
- 年：2016
- 卷：42
- 期：Complete
- 页码：1-3
- 全文大小：457 K
文摘
- •
Single- and multiple-dose pharmacokinetics of ethambutol (EMB) and rifampicin (RIF) in a patient requiring both ECMO and renal replacement therapy are reported for the first time.
- •
Extended dialysis eliminates EMB effectively and to a larger extent than regular intermittent haemodialysis in outpatients.
- •
Also RIF, previously reported to be non-dialysable, could be found in the spent dialysate.
- •
There was no detectable effect of the ECMO membrane on the removal of both drugs.
- •
We conclude that after an initial dose, as for patients without renal impairment (15 mg/kg/day), therapeutic drug monitoring should be used to guide EMB dosing in patients undergoing extended daily dialysis.